OncoMatch/Clinical Trials/NCT06588413
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
Is NCT06588413 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Olanzapine for multiple myeloma.
Treatment: Olanzapine — Patients who receive a chemotherapy called melphalan are at high risk of having nausea and vomiting. A medication called olanzapine has been shown to decrease nausea and vomiting after chemotherapy. A previous research study found the 10 mg dose of olanzapine (combined with 3 standard medications used routinely to prevent nausea/vomiting) to be effective for patients who received melphalan chemotherapy, but several other studies have shown many patients have a side effect of sleepiness (e.g., sedation) with that dose of the medication. Our study will compare two lower doses of olanzapine (5 mg and 2.5 mg) in combination with the 3 standard medications used to prevent nausea/vomiting in the patients who receive melphalan chemotherapy to determine which dose is effective in preventing nausea and vomiting with the lowest amount of sleepiness side effect.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Prior therapy
Must have received: high-dose melphalan (melphalan) — 140-200 mg/m2
Receipt of high-dose melphalan 140-200 mg/m2
Must have received: autologous stem cell transplant
Autologous stem cell transplantation recipient
Cannot have received: antipsychotic agent (risperidone, quetiapine, clozapine, phenothiazine, butyrophenone)
Treatment with other antipsychotic agents such as risperidone, quetiapine, clozapine, phenothiazine, or butyrophenone within 30 days prior to enrollment or planned during protocol therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Wellstar MCG · Augusta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify